Levodopa-induced dyskinesia in Parkinson's disease drug pipeline
- Subtype of Parkinson's disease
Involuntary movements from chronic levodopa therapy in Parkinson's disease; a distinct treatment target from the underlying disease.
1 compound from 1 company is in active clinical development for levodopa-induced dyskinesia in parkinson's disease.
1Compound
1Company
0Phase 3+
Mechanisms: Small molecule (1)
Pipeline data compiled October 2026 · every fact sourced.
Compounds in development (1)
| Compound | Company | Phase | Status | Mechanism |
|---|---|---|---|---|
| AV-101 (L-4-chlorokynurenine) | Vistagen Therapeutics, Inc. | Phase 1 | Suspended | NMDA receptor Antagonist |
Trials recruiting now
1 registered interventional levodopa-induced dyskinesia in parkinson's disease trial — none recruiting at present. Browse all on ClinicalTrials.gov →
Frequently asked
- How many drugs are in development for levodopa-induced dyskinesia in parkinson's disease?
- 1 compound from 1 company is in active clinical development for levodopa-induced dyskinesia in parkinson's disease.